Personalized antiseizure medication therapy in critically ill adult patients

Abstract

Precision medicine has the potential to have a significant impact on both drug development and patient care. It is crucial to not only provide prompt effective antiseizure treatment for critically ill patients after seizures start but also have a proactive mindset and concentrate on epileptogenesis and the underlying cause of the seizures or seizure disorders. Critical illness presents different treatment issues compared with the ambulatory population, which makes it challenging to choose the best antiseizure medications and to administer them at the right time and at the right dose. Since there is a paucity of information available on antiseizure medication dosing in critically ill patients, therapeutic drug monitoring is a useful tool for defining each patient's personal therapeutic range and assisting clinicians in decision‐making. Use of pharmacogenomic information relating to pharmacokinetics, hepatic metabolism, and seizure etiology may improve safety and efficacy by individualizing therapy. Studies evaluating the clinical implementation of pharmacogenomic information at the point‐of‐care and identification of biomarkers are also needed. These studies may make it possible to avoid adverse drug reactions, maximize drug efficacy, reduce drug–drug interactions, and optimize medications for each individual patient. This review will discuss the available literature and provide future insights on precision medicine use with antiseizure therapy in critically ill adult patients.

Status Epilepticus: An Update on Pharmacological Management

“…Continuous intravenous anesthetic medications for refractory status epilepticus5,6,43,54,61 Status Epilepticus: Update on Management Almohaish et al 329…”

“…Antiseizure medication alternative intermittent treatment options for refractory status epilepticus5,6,54,[57][58][59]61 …”

“…Antiseizure medications and dosing in status epilepticus5,6,26,[29][30][31][32][33][34][35][36][37][38]61 …”